Multiple myeloma

Klinicka Onkologie

Volumn 24, Issue SUPPL., 2011, Pages

  Hájek, Roman ^a,b   Krejci M ^a   Pour, L ^a   Adam, Z ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Diagnostics; Multiple myeloma; Treatment

Indexed keywords

ALBUMIN; ALPHA INTERFERON; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CALCIUM; CARFILZOMIB; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; THALIDOMIDE;

ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; DRUG EFFICACY; DRUG MEGADOSE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; KIDNEY FAILURE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEUROSURGERY; ORTHOPEDIC SURGERY; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PLASMA CELL; SPINAL CORD COMPRESSION; VERTEBRA FRACTURE;

HUMANS; MULTIPLE MYELOMA; PROGNOSIS;

EID: 79959928394     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Adam Z, Bačovský J, Flochová E et al. Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou, Myelomovou sekcí České hematologické společnosti a experty Slovenské republiky pro diagnostiku a léčbu mnohočetného myelomu. Transfuze Hematol Dnes 2005; 11 (Suppl 1): 3-50.
2. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149(3): 334-351.
3. Pichiorri F, Suh SS, Ladetto M et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105(35): 12885-12890.
4. Hájek R, Adam Z, Maisnar V et al. Souhrn doporučení 2009 "Diagnostika a léčba mnohočetného myelomu". Doporučení vypracované Českou myelomovou skupinou, Myelomovou sekcí České hematologické společnosti a experty Slovenské republiky pro diagnostiku a léčbu mnohočetného myelomu. Transfuze a hematologie dnes 2009; 15 (Suppl 3): 5-80.
5. Greslikova H, Zaoralova R, Filkova H et al. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. Neoplasma 2010; 57(2): 111-117.
6. Munshi NC, Avet-Loiseau H Genomics in multiple myeloma. Clin Cancer Res 2011; 17(6): 1234-1242.
7. Yaccoby S Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol 2010; 149(3): 311-321.
8. Pour L, Svachova H, Adam Z et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 2010; 89(4): 385-389.
9. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group Br J Haematol 2003; 121 (5): 749-757.
10. Bladé J, Rosin̄ol L, Cibeira MT et al. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115(18): 3655-3663.
11. Novitzky N, Thomson J, Thomas V et al. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma. Biol Blood Marrow Transplant 2010; 16(10): 1402-1410.
12. Barlogie B, Anaissie E, van Rhee F et al. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol 2010; 28(18): 3023-3027.
13. Attal M, Lauwers VC, Marit G et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: Final analysis of the IFM 2005-02. Proc ASH 2010: Abstract 310.
14. Adam Z, Ševčík P, Vorlíček J. Nádorová kostní choroba. 1. vyd. Praha: Grada 2005
15. Attal M, Cristini C, Marit G et al Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol 2010; 28(15s): Abstract 8018.
16. Zeldis JB, Knight R, Hussein M et al. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci 2011; 1222(1): 76-82
17. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23(15): 3412-3420.
18. Munshi NC, Anderson KC, Bergsagel PL et al Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011; 117(18): 4696-4700.
19. Engelhardt M, Udi J, Kleber M et al. European Myeloma Network. the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma 2010; 51(11): 2006-2011